

27. Žižiková K. Osteofibrózní dysplazie Campanacci. *Československá radiologie* 1993; 47: 22–23.
28. Matenalli H, Meisner J. Výskyt fibrózní dysplazie. *Československá pediatrie* 1994; 49: 441–442.
29. Koudelová J, Koudela K, Kunešová M, et al. Metafyzární fibrózní defekt. *Acta chirurgicae orthopaedicae et traumatologiae Čechoslovaca* 2005; 72: 355–362.
30. Heuer L, Hrušák D, Andrlé P, et al. Benigní fibrooseální léze čelistních kostí. *StomaTeam (Praha)* 2011; 11: 19–25.
31. Povýšil C, Matějovský Z, Horák M. Klasický adamantinom, diferencovaný adamantinom a osteofibrózní dysplazie dlouhých kostí. *Časopis lékařů českých* 2004; 143: 329–335.
32. Mazánek J, Povýšil C, Dobrová M. Neobvyklé klinické obrazy fibrózní dysplazie. *Česká stomatologie a Praktické zubní lékařství* 1998; 46: 48–62.
33. Šírůček P, Hodan R, Havel M. Neobvyklá příčina zduření mandibuly. *První linie* 2012; 2: 8–9.
34. Statelová D, Sítár J, Stiffel W. Fibrózní dysplázie maxilofaciálního skeletu. *Stomatolog (Martin)* 1999; 9: 15–17.
35. Poruban D, Chynoranský M, Kurill E. Fronto-orbito-zygomaticko-maxilární fibrózní dysplázie - Kazuistika. *Stomatolog (Martin)* 1999; 9: 37–39.
36. Zídková H, Kolář J, Matějovský Z. Aggressive features of pelvic fibrous dysplasia. *RöFo. Fortschritte auf dem Gebiete der Röntgenstrahlen und der neuen bildgebenden Verfahren* 1994; 161: 183–185.
37. Ebata K, Usami T, Tohna I, et al. Chondrosarcoma and osteosarcoma arising in polyostotic fibrous dysplasia. *J Oral Maxillofac Surg* 1992; 50: 761–764.
38. Kaushik S, Smoker WR, Frable WJ. Malignant transformation of fibrous dysplasia into chondroblastic osteosarcoma. *Skeletal radiology* 2002; 31: 103–106.
39. Diniz AF, Filho JA, Alencar RC, et al. Low-grade central osteosarcoma of the mandible: a case study report. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2007; 103: 246–252.
40. Bertoni F, Fernando Arias L, Alberghini M, et al. Fibrous dysplasia with degenerative atypia: a benign lesion potentially mistaken for sarcoma. *Arch Pathol Lab Med* 2004; 128: 794–796.
41. Khairallah E, Antonyshyn O, Farb R, et al. Progressive unilateral mandibular swelling in adolescence: a diagnostic dilemma. *J Craniofac Surg* 1997; 8: 32–37.
42. Ruggieri P, Sim FH, Bond JR, et al. Malignancies in fibrous dysplasia. *Cancer* 1994; 73: 1411–1424.
43. Plotkin H, Rauch F, Zeitlin L. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. *J Clin Endocrinol Metab* 2003; 88: 4569–4575.
44. Matarazzo P, Lala R, Masi G, et al. Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome. *J Pediatr Endocrinol Metab* 2002; 15(Suppl. 3): 929–937.
45. Chan B, Zacharin M. Pamidronate treatment of polyostotic fibrous dysplasia: failure to prevent expansion of dysplastic lesions during childhood. *J Pediatr Endocrinol Metab* 2006; 19: 75–80.
46. Chao K, Katznelson L. Use of high-dose oral bisphosphonate therapy for symptomatic fibrous dysplasia of the skull. *Journal of neurosurgery* 2008; 109: 889–892.
47. Majoor BC, Appelman-Dijkstra NM, et al. Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia. *J Bone Miner Res* 2017; 32: 264–276.
48. Florez H, Peris P, Vidal-Sicart S, et al. Lack of scintigraphic response of fibrous dysplasia to bisphosphonate treatment. *Rheumatology (Oxford)* 2016; 55: 1735.
49. Chapurlat RD, Gensburger D, Jimenez-Andrade JM, et al. Pathophysiology and medical treatment of pain in fibrous dysplasia of bone. *Orphanet J Rare Dis* 2012; 7(Suppl. 1): S3.
50. Chapurlat RD. Medical therapy in adults with fibrous dysplasia of bone. *J Bone Miner Res* 2006; 21(Suppl. 2): P114–P119.
51. Kitagawa Y, Tamai K, Ito H. Oral alendronate treatment for polyostotic fibrous dysplasia: a case report. *J Orthop Sci* 2004; 9: 521–515.
52. Mansoori LS, Catel CP, Rothman MS. Bisphosphonate treatment in polyostotic fibrous dysplasia of the cranium: case report and literature review. *Endocr Pract* 2010; 16: 851–854.
53. Wu D, Ma J, Bao S, et al. Continuous effect with long-term safety in zoledronic acid therapy for polyostotic fibrous dysplasia with severe bone destruction. *Rheumatol Int* 2015; 35: 767–772.
54. Benhamou J, Gensburger D, Chapurlat R. Transient improvement of severe pain from fibrous dysplasia of bone with denosumab treatment. *Joint Bone Spine* 2014; 81: 549–550.
55. Ganda K, Seibel MJ. Rapid biochemical response to denosumab in fibrous dysplasia of bone: report of two cases. *Osteoporos Int* 2014; 25: 777–782.
56. Boyce AM, Kelly MH, Brillante BA, et al. A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone. *J Clin Endocrinol Metab* 2014; 99: 4133–4140.
57. Simm PJ, Biggin A, Zacharin MR, et al. Bone Mineral Working Group. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. *J Paediatr Child Health* 2018; 54: 223–233.
58. Lee JS, Fitz Gibbon EJ, Chen YR, et al. Clinical guidelines for the management of craniofacial fibrous dysplasia. *Orphanet J Rare Dis* 2012; 7(Suppl. 1): S2.
59. Povýšil C, et al. Patomorfologie chorob kostí a kloubů. Praha: Galén 2017, 409 s.



SLEDUJTE NÁS NA TWITTERU

@MedicalSolen

časopisy / konference

20 let s vámi
SOLEN
MEDICAL EDUCATION

twitter.com/
@MedicalSolen

Nenechte si ujít aktuální informace o možnostech postgraduálního vzdělávání lékařů a lékárníků